Literature DB >> 19729928

The discovery of oligoclonal bands: a 50-year anniversary.

Trygve Holmøy1.   

Abstract

The discovery of the oligoclonal IgG bands (OCB) in the cerebrospinal fluid (CSF) was a major step forward in the understanding of multiple sclerosis (MS) and other inflammatory diseases of the central nervous system. Separation of IgG molecules produced by different B cell clones was not possible until agar electrophoresis was invented in 1950. The key observation that led to the discovery of OCB can be dated back to 1959, when Karcher, van Sande and Lowenthal reported that agar electrophoresis subdivided CSF gamma-globulins from a patient with subacute sclerosing panencephalitis into several individual fractions, which were distinguishable with densitometry. OCB were detected in CSF from patients with trypanosomiasis, neurosyphilis and MS by the same research group in 1960. The discovery of OCB was preceded by the detection of intrathecal IgG synthesis with Tiselilus' moving boundary electrophoresis by Kabat in 1942. This method did not allow separation of IgG molecules produced by different B cell clones, and it is therefore a misconception that Kabat discovered the OCB. The discovery of OCB led to the still prevailing concept that MS is mediated by clonally expanded lymphocytes, and provided the basis for modern diagnostic procedures in MS. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19729928     DOI: 10.1159/000235944

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  11 in total

1.  Antigen microarrays identify CNS-produced autoantibodies in RRMS.

Authors:  F J Quintana; M F Farez; G Izquierdo; M Lucas; I R Cohen; H L Weiner
Journal:  Neurology       Date:  2012-01-18       Impact factor: 9.910

2.  Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients.

Authors:  Kelly Fellows; Tomas Uher; Richard W Browne; Bianca Weinstock-Guttman; Dana Horakova; Helena Posova; Manuela Vaneckova; Zdenek Seidl; Jan Krasensky; Michaela Tyblova; Eva Havrdova; Robert Zivadinov; Murali Ramanathan
Journal:  J Lipid Res       Date:  2015-08-04       Impact factor: 5.922

3.  Antibodies in multiple sclerosis oligoclonal bands target debris.

Authors:  Ryan C Winger; Scott S Zamvil
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-28       Impact factor: 11.205

4.  Distinct oligoclonal band antibodies in multiple sclerosis recognize ubiquitous self-proteins.

Authors:  Simone M Brändle; Birgit Obermeier; Makbule Senel; Jessica Bruder; Reinhard Mentele; Mohsen Khademi; Tomas Olsson; Hayrettin Tumani; Wolfgang Kristoferitsch; Friedrich Lottspeich; Hartmut Wekerle; Reinhard Hohlfeld; Klaus Dornmair
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-20       Impact factor: 11.205

Review 5.  Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis.

Authors:  Finn Sellebjerg; Diego Cadavid; Deborah Steiner; Luisa Maria Villar; Richard Reynolds; Daniel Mikol
Journal:  Ther Adv Neurol Disord       Date:  2016-01       Impact factor: 6.570

Review 6.  A case for regulatory B cells in controlling the severity of autoimmune-mediated inflammation in experimental autoimmune encephalomyelitis and multiple sclerosis.

Authors:  Avijit Ray; Monica K Mann; Sreemanti Basu; Bonnie N Dittel
Journal:  J Neuroimmunol       Date:  2010-12-10       Impact factor: 3.478

7.  The Sexual Dimorphism in Cerebrospinal Fluid Protein Content Does Not Affect Intrathecal IgG Synthesis in Multiple Sclerosis.

Authors:  Massimiliano Castellazzi; Caterina Ferri; Ginevra Tecilla; André Huss; Paola Crociani; Gaetano Desina; Gianvito Barbella; Alice Piola; Samantha Permunian; Makbule Senel; Maurizio Leone; Hayrettin Tumani; Maura Pugliatti
Journal:  J Pers Med       Date:  2022-06-16

Review 8.  Lipids and lipid-reactive antibodies as biomarkers for multiple sclerosis.

Authors:  Francisco J Quintana; Ada Yeste; Howard L Weiner; Ruxandra Covacu
Journal:  J Neuroimmunol       Date:  2012-05-12       Impact factor: 3.478

9.  Potential impact of B cells on T cell function in multiple sclerosis.

Authors:  Sara Ireland; Nancy Monson
Journal:  Mult Scler Int       Date:  2011-03-24

Review 10.  Comparison of the Efficacy and Safety of Anti-CD20 B Cells Depleting Drugs in Multiple Sclerosis.

Authors:  Kelly R Cotchett; Bonnie N Dittel; Ahmed Z Obeidat
Journal:  Mult Scler Relat Disord       Date:  2021-01-22       Impact factor: 4.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.